Envarsus xr and Photosensitivity reaction - a phase IV clinical study of FDA data

Summary:

Photosensitivity reaction is reported as a side effect among people who take Envarsus xr (tacrolimus), especially for people who are male, 50-59 old, also take Amlodipine, and have Dyslipidaemia.

The phase IV clinical study analyzes which people have Photosensitivity reaction when taking Envarsus xr. It is created by eHealthMe based on reports of 3,807 people who have side effects when taking Envarsus xr from the FDA, and is updated regularly.

What is Envarsus xr?

Envarsus xr has active ingredients of tacrolimus. eHealthMe is studying from 3,819 Envarsus xr users. Check the latest studies of Envarsus xr.

What is Photosensitivity reaction?

Photosensitivity reaction is found to be associated with 1,048 drugs and 1,262 conditions by eHealthMe. Check the latest studies of Photosensitivity reaction.

On Jul, 15, 2026

3,807 people reported to have side effects when taking Envarsus xr.
Among them, 12 people (0.32%) have Photosensitivity reaction.

Could Envarsus xr cause Photosensitivity reaction?

Among these 12 people:

What is the gender of people who have Photosensitivity reaction when taking Envarsus xr? *

female: 20 %
male: 80 %

What is the age of people who have Photosensitivity reaction when taking Envarsus xr? *

What are other drugs people take besides Envarsus xr? *

What are other side effects people have besides Photosensitivity reaction? *

Rashes (redness): 10 people, 83.33%
Lip Ulceration (ulcer of lip): 10 people, 83.33%
Burns Second Degree: 10 people, 83.33%
Hypoprothrombinaemia (blood disorder in which a deficiency of prothrombin (factor ii) results in impaired blood clotting): 2 people, 16.67%
Skin Discoloration: 1 person, 8.33%
Premature Baby: 1 person, 8.33%
Muscle Spasms (muscle contraction): 1 person, 8.33%
Foetal Exposure During Pregnancy (exposing your unborn child to contraindicated in pregnancy leads birth defect): 1 person, 8.33%
Blood Bilirubin Increased: 1 person, 8.33%

What are the existing conditions these people have? *

High Blood Pressure: 10 people, 83.33%
Dyslipidaemia (abnormal amount of lipids): 10 people, 83.33%
Antiphospholipid Syndrome (disorder that manifests clinically as recurrent venous or arterial thrombosis and/or fetal loss): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Envarsus xr and have Photosensitivity reaction?

- Check whether Photosensitivity reaction is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Envarsus xr:

Envarsus xr (3,819 reports)

Browse all side effects of Envarsus xr:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Photosensitivity reaction:

Photosensitivity reaction (1,048 drugs)

Browse all the conditions that are associated with Photosensitivity reaction:

Photosensitivity reaction (1,262 conditions)

Related publications that referenced our studies

Stricklin SM, Stoecker WV, Rader RK, Hood AF, Litt JZ, Schuman TP, "Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia?)", Dermatology online journal, 2012 Feb .
Kocamaz, M., & Karadag, O., "Topiramate-Induced Acute Myopia, Diplopia, and Photosensitivity: A Case Report", Beyoglu Eye Journal, 2019 Jan .
Stricklin SM, Stoecker WV, Rader RK, Hood AF, Litt JZ, Schuman TP, "Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia?)", Dermatology online journal, 2012 Feb .
Kocamaz, M., & Karadag, O., "Topiramate-Induced Acute Myopia, Diplopia, and Photosensitivity: A Case Report", Beyoglu Eye Journal, 2019 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on tacrolimus (the active ingredients of Envarsus xr) and Envarsus xr (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.